• Home
  • Sector News
    • Technology
    • Energy
    • Financial Services
  • Opinion and Analysis
    • Market Overview
      • Opinion
      • Technical Analysis
      • Fundamental Analysis
      • Investment Idea
    • Stock Market
      • Opinion
      • Technical Analysis
      • Fundamental Analysis
      • Stock Pick
  • Virtus Report

Subscribe to stay informed!

Discover hidden stock market gems and stay up to date with our weekly email newsletter and individual stock ideas

What's Hot

Kristen Welker to Take Over as Host of NBC’s ‘Meet the Press’ from Chuck Todd

June 4, 2023

BlackRock Multi-Sector Income Trust (BIT) Announces $0.12 Dividend

June 4, 2023

OPEC+ Meeting to Discuss Production Quotas and Potential Cuts

June 4, 2023
Telegram RSS
  • Government
  • Press Releases
  • Stock Market
  • Top Stories
  • Trading Insights
  • Trending
Telegram RSS
Virtus Junxit EquitiesVirtus Junxit Equities
  • Home
  • Sector News
    1. Technology
    2. Energy
    3. Financial Services
    4. View All

    Former Amazon Employee Reveals the Reason Behind Layoffs in Large Tech Companies

    June 3, 2023

    Bad Bunny’s Secret: Taking Breaks from Social Media Helps Him Feel Better

    June 3, 2023

    Vintage 2008 Video Shows Musk Presenting SpaceX’s Vision

    June 3, 2023

    Cathie Wood reduced her stake in Microsoft but increased holdings in PagerDuty and Ginkgo Bioworks

    June 3, 2023

    The Corn & Ethanol Report: Anticipating the Drought Monitor

    June 2, 2023

    Natural Gas Prices Increase as Risk Assets Rise

    June 2, 2023

    Crude Oil Prices Rise Prior to OPEC+ Meeting

    June 2, 2023

    Predicting Corn, Soybean, and Wheat Prices for June

    June 2, 2023

    ‘Fearless’ Taylor Swift Passes Madonna On Richest Self-Made Women List — Here’s Who Else The ‘All Too Well’ Singer Ranks Ahead Of – Live Nation Entertainment (NYSE:LYV)

    June 3, 2023

    Don’t let investment jargon intimidate you!

    June 3, 2023

    Grain Market Continues to be Volatile Ahead of Weekend – Corn, Soybeans, and Wheat Prices Being Closely Monitored

    June 2, 2023

    Chevron’s Attracts Investors Looking for Value and Short-Term Gains by Selling Out-of-the-Money Puts

    June 2, 2023

    Kristen Welker to Take Over as Host of NBC’s ‘Meet the Press’ from Chuck Todd

    June 4, 2023

    BlackRock Multi-Sector Income Trust (BIT) Announces $0.12 Dividend

    June 4, 2023

    OPEC+ Meeting to Discuss Production Quotas and Potential Cuts

    June 4, 2023

    1 Under-the-Radar Growth Stock to Buy In June

    June 4, 2023
  • Opinion and Analysis
    • Market Overview
      • Opinion
      • Technical Analysis
      • Fundamental Analysis
      • Investment Idea
    • Stock Market
      • Opinion
      • Technical Analysis
      • Fundamental Analysis
      • Stock Pick
  • Virtus Report
Get Access
Virtus Junxit EquitiesVirtus Junxit Equities
Home»Stock Market»Citigroup continues to recommend buying Arcus Biosciences (RCUS)
Stock Market

Citigroup continues to recommend buying Arcus Biosciences (RCUS)

JamesBy JamesMay 27, 2023Updated:May 27, 2023No Comments2 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email

Citigroup has maintained its Buy recommendation for Arcus Biosciences (NYSE:RCUS). The average one-year price target for Arcus Biosciences is $43.86, with a range from $22.22 to $73.50. This represents a potential increase of 99.09% from its latest reported closing price of $22.03.

As of May 26, 2023, there are 469 funds or institutions reporting positions in Arcus Biosciences. The put/call ratio of RCUS is 0.41, indicating a bullish outlook.

Notable shareholders of Arcus Biosciences include iShares Core S&P Small-Cap ETF, which holds 3,803K shares representing 5.20% ownership of the company, Biotechnology Portfolio, which holds 3,193K shares representing 4.37% ownership, and Octagon Capital Advisors, which holds 2,172K shares representing 2.97% ownership. Citadel Advisors holds 1,766K shares representing 2.42% ownership, and recently increased its portfolio allocation in RCUS by 97.83% over the last quarter.

Arcus Biosciences is an oncology-focused biopharmaceutical company with four molecules in clinical development, including Etrumadenant, the first dual A2a/A2b adenosine receptor antagonist to enter the clinic, AB680, the first small-molecule CD73 inhibitor to enter the clinic, Domvanalimab, an anti-TIGIT monoclonal antibody, and a new potential immuno-oncology backbone therapy.

Key filings for Arcus Biosciences can be found on the company’s website.

This article was originally published on Fintel, and the views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Previous ArticleFractional Investing: Access the Stock Market with Less Money
Next Article Central Securities (CET) Announces $0.20 Dividend Payment
James

    Related Posts

    Price Target for Edita Food Industries SAE (LSE:EFID) Reduced by 13.25% to 2.54

    June 4, 2023By James0

    ITC (NSE:ITC) Price Target Increased to 470.55, Representing a 6.74% Rise

    June 4, 2023By James0

    Genfit (EPA:GNFT) Price Target Decreased by 11.94% to 8.02

    June 4, 2023By James0

    Leave A Reply Cancel Reply

    Our Picks

    Prime Minister’s Schedule for Sunday, June 4, 2023

    June 4, 2023

    Apareció Foundation’s Felix Magazine Launches New Issue Focusing on Wellness & Beauty, Featuring Sam Asghari

    June 4, 2023

    Bridging the Information Gap in Healthcare

    June 4, 2023

    SBI Launches Countrywide Search for Companies to Create Custom Board Games

    June 4, 2023
    Stay In Touch
    • Facebook
    • Twitter
    • Pinterest
    • Instagram
    • YouTube
    • Vimeo
    Don't Miss

    BlackRock Multi-Sector Income Trust (BIT) Announces $0.12 Dividend

    Trending June 4, 2023

    On June 1, 2023, BlackRock Multi-Sector Income Trust revealed that it has officially announced a monthly dividend of $0.12 per share ($1.48 annualized). The company had previously paid $0.12 per share in dividends. To qualify for the dividend, shares must be acquired before the ex-dividend date of June 14, 2023.…

    1 Under-the-Radar Growth Stock to Buy In June

    June 4, 2023

    Price Target for Edita Food Industries SAE (LSE:EFID) Reduced by 13.25% to 2.54

    June 4, 2023

    Top Three REIT Stocks to Consider Purchasing in June

    June 4, 2023
    FEATURED INSIGHTS​

    Virtus Junxit Equity Report: Loop Media, Inc. (AMEX: LPTV)

    May 31, 2023

    Virtus Junxit Equity Research: Hillstream BioPharma, Inc. (NASDAQ: HILS)

    May 18, 2023

    NeuroOne Medical NMTC Extreme Potential in Medical Tech

    May 14, 2023

    EZFill Holdings (EZFL) – An In-Depth Analysis of the Company’s Market Dynamics, Financials, and Upcoming Catalysts

    May 8, 2023

    Subscribe to stay informed!

    Discover hidden stock market gems and stay up to date with our weekly email newsletter and individual stock ideas

    Telegram RSS
    • Home
    • Privacy Policy
    • Disclaimer
    • Virtus Report
    • Get Access
    © 2023 Virtus Junxit LLC

    Type above and press Enter to search. Press Esc to cancel.